Helix Acquisition Corp. II Price & Performance (HLXB)

Neurotech Pharmaceuticals has received FDA approval for its cell therapy implant, Encelto, designed to treat idiopathic macular telangiectasia type 2. This marks a significant advancement in cell therapy applications for eye diseases, offering new hope for patients with this previously untreatable condition.1

Helix Acquisition Corp. II has announced a merger with BridgeBio Oncology Therapeutics to form a publicly listed biotech company. The deal, backed by $450 million in funding, will support clinical trials for cancer therapies targeting RAS and PI3Kα malignancies, advancing innovative treatments for challenging cancers.234

Helix Exploration PLC has scheduled the drilling of two additional wells in Montana. This development reflects the company’s ongoing efforts to enhance its exploration activities and capitalize on potential resources in the region, aiming to strengthen its position in the energy sector.5